TrialNature medicine2025

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.

Ramez N Eskander et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.